The Company intends to use the proceeds to fund its drug development activities and for general corporate purposes. The securities described above were offered and sold by the Company pursuant to a registration statement filed with the Securities and Exchange Commission (SEC), which became effective on December 1, 2010.
"In only a few short months since adding our new co-evaporation capability and control approach to our CIGS process development, we've achieved efficiencies of over 14 percent," said Chief Technology Officer, XsunX, Inc., Robert G. Wendt. "This efficiency level and the efficiency distribution is a significant achievement. In addition to achieving high efficiency levels, we demonstrated excellent cell voltage in the range of 620 to 660 millivolt (mV) clearly demonstrating the incorporation of gallium near the junction in the cell structure which is necessary for producing high efficiencies. We are working hard to further improve on this rapid success so that we can deliver the best possible CIGS technology to the market."
Deposition of the CIGS cell layers was conducted on full size 125 mm square substrates. Test configurations used to
The T-EOR Platform, a new and innovative industry oil production system, is a turnkey integrated and portable oil recovery platform that can be deployed quickly and economically to recover oil from previously producing oil wells with known oil reserves that have not been fully developed. The company has identified over 6,000 abandoned wells in the State of Texas alone that are potential oil producing candidates for the T-EOR Platform.....
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive top-line results from its Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the response of two patient groups to CORLUX treatment: one included patients who were glucose intolerant and one included patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved for both groups: with 60% responding in the glucose intolerant group and 43% in the hypertensive group. An initial review of safety data indicates that CORLUX was well tolerated by Cushing's Syndrome patients in this Phase 3 study. "The results of the study demonstrate that CORLUX has the potential to become an important treatment option for patients suffering from Cushing's Syndrome," said Joseph Belanoff, M.D., Chief Executive Officer of Corcept. "We remain on track to submit a New Drug Application (NDA) to the FDA for CORLUX in Cushing's Syndrome by the end of the first quarter of 2011 and continue to work toward our goal of making CORLUX available to patients with this severe disease."
has completed its testing and has approved for Oil production field use, its first Transportable Enhanced Oil Recovery (T-EOR) Platform. The company announced it took delivery of the first T-EOR Platform on September 29, 2010. The T-EOR Platform is now on route to the company's Chilson A and B properties for its first field use.
The T-EOR Platform, a new and innovative industry oil production system, is a turnkey integrated and portable oil recovery platform that can be deployed quickly and economically to recover oil from previously producing oil wells with known oil reserves that have not been fully developed. The company has identified over 6,000 abandoned wells in the State of Texas alone that are potential oil producing candidates for the T-EOR Platform.
Please refer to this post to find up to date news for SIRI stock.
